VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Monday, January 5, 2026
Stock Comparison
Deutsche Boerse AG vs Sanofi
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Deutsche Boerse AG
DB1 · Xetra
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Deutsche Boerse AG's moat claims, evidence, and risks.
View DB1 analysisSanofi
SAN · Euronext Paris
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Comparison highlights
- Moat score gap: Deutsche Boerse AG leads (81 / 100 vs 74 / 100 for Sanofi).
- Segment focus: Deutsche Boerse AG has 8 segments (28.2% in Securities Services (Clearstream: ICSD/CSD settlement + custody)); Sanofi has 3 segments (79.8% in Pharma (Prescription Medicines)).
- Primary market structure: Duopoly vs Oligopoly. Pricing power: Moderate vs Moderate.
- Moat breadth: Deutsche Boerse AG has 12 moat types across 5 domains; Sanofi has 5 across 3.
Primary market context
Deutsche Boerse AG
Securities Services (Clearstream: ICSD/CSD settlement + custody)
Securities settlement and custody infrastructure (ICSD/CSD) for Eurobonds and domestic markets
Global (Eurobonds + multiple domestic markets)
Custodian banks, broker-dealers, central banks, institutional investors
Settlement/custody infrastructure and asset servicing
28.2%
Sanofi
Pharma (Prescription Medicines)
Branded prescription pharmaceuticals (immunology, rare disease, neurology, oncology, general medicines)
Global
Patients via payers/providers and channel partners (wholesalers, pharmacies, hospitals)
Research-based drug developer, manufacturer, and marketer
79.8%
Side-by-side metrics
Moat coverage
Shared moat types
Deutsche Boerse AG strengths
Sanofi strengths
Segment mix
Deutsche Boerse AG segments
Full profile >Financial Derivatives (Eurex trading + Eurex Clearing)
Oligopoly
Commodities (EEX marketplaces + clearing)
Oligopoly
Cash Equities (Xetra + Boerse Frankfurt)
Quasi-Monopoly
FX & Digital Assets (360T + Crypto Finance)
Competitive
Securities Services (Clearstream: ICSD/CSD settlement + custody)
Duopoly
Fund Services (Vestima fund processing + Fund Centre distribution)
Oligopoly
Software Solutions (SimCorp + Axioma Analytics)
Competitive
ESG & Index (ISS STOXX: indices + ESG/governance data)
Oligopoly
Sanofi segments
Full profile >Pharma (Prescription Medicines)
Oligopoly
Vaccines
Oligopoly
Opella (Consumer Healthcare - Sanofi minority stake)
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.